Cargando…
Correction: Corrigendum: IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
Autores principales: | Wee, Zhen Ning, Yatim, Siti Maryam J. M., Kohlabauer, Vera K., Feng, Min, Goh, Jian Yuan, Bao, Yi, Lee, Puay Leng, Zhang, Songjing, Wang, Pan Pan, Lim, Elgene, Tam, Wai Leong, Cai, Yu, Ditzel, Henrik J., Hoon, Dave S. B., Tan, Ern Yu, Yu, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188469/ https://www.ncbi.nlm.nih.gov/pubmed/26585835 http://dx.doi.org/10.1038/ncomms10054 |
Ejemplares similares
-
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel
por: Wee, Zhen Ning, et al.
Publicado: (2015) -
Ginsenoside panaxatriol reverses TNBC paclitaxel resistance by inhibiting the IRAK1/NF-κB and ERK pathways
por: Wang, Panpan, et al.
Publicado: (2020) -
The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
por: Law, Andrew M K, et al.
Publicado: (2017) -
Corrigendum
Publicado: (2012) -
Corrigendum
Publicado: (2012)